Stockreport

Regeneron outlines 18 new Phase III studies and expects four FDA approvals in 2026 while advancing EYLEA HD and DUPIXENT growth [Seeking Alpha]

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF CEO Leonard Schleifer reported "fourth quarter total revenue up 3% year-over-year, driven by double-digit net sales growth for 3 of our leading products." Schleifer hig [Read more]